Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

The Mammalian Target of Rapamycin Complex 2 Controls Folding and Stability of Akt and Protein Kinase C

Amino Acid Regulation of TOR Complex 1.

mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Regulatory Function of Phosphorylation and Ubiquitination on The TORC1 Signaling Pathway

Cross-talk between Sirtuin and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in the Regulation of S6 Kinase 1 (S6K1) Phosphorylation

AKT-mediated phosphorylation of TSC2 controls stimulus and tissue-specific mTORC1 signaling and organ growth

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

mTORC2: The other mTOR in autophagy regulation

mTORC2: a multifaceted regulator of autophagy

mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity

mTORC1-CTLH E3 ligase regulates the degradation of HMG-CoA synthase 1 through the Pro/N-degron pathway

mTOR coordinates protein synthesis, mitochondrial activity and proliferation

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

RagC phosphorylation autoregulates mTOR complex 1

mTORC1 phosphorylates and stabilizes LST2 to negatively regulate EGFR

The Structure of Mtor Complexes at a Glance

Structural Insights of Mtor Complex 1

mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress

Regulation Of Mtorc1 By The Rab And Arf Gtpases

The mTORC2 signaling network: targets and cross-talks